New drug aims to calm kidney attack by antibodies
NCT ID NCT07571746
First seen May 28, 2026
Summary
This study tests a drug called surovatamig in 43 adults with primary membranous nephropathy, a kidney disease caused by antibodies attacking the kidneys. The drug is given as a shot under the skin. Researchers want to see if it is safe and can reduce protein in the urine, which is a sign of kidney damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
WITHDRAWNCréteil, 94010, France
-
Research Site
NOT_YET_RECRUITINGLos Angeles, California, 90095, United States
-
Research Site
NOT_YET_RECRUITINGIowa City, Iowa, 52242, United States
-
Research Site
NOT_YET_RECRUITINGBethesda, Maryland, 20889, United States
-
Research Site
NOT_YET_RECRUITINGNew York, New York, 10016, United States
-
Research Site
RECRUITINGHouston, Texas, 77027, United States
-
Research Site
NOT_YET_RECRUITINGHouston, Texas, 77030, United States
-
Research Site
NOT_YET_RECRUITINGIeper, 8900, Belgium
-
Research Site
NOT_YET_RECRUITINGBordeaux, 33076, France
-
Research Site
NOT_YET_RECRUITINGLyon, 69009, France
-
Research Site
NOT_YET_RECRUITINGNantes, 44093, France
-
Research Site
NOT_YET_RECRUITINGNîmes, 30029, France
-
Research Site
NOT_YET_RECRUITINGDüsseldorf, 40225, Germany
-
Research Site
NOT_YET_RECRUITINGBrescia, 25123, Italy
-
Research Site
NOT_YET_RECRUITINGRozzano, 20089, Italy
-
Research Site
NOT_YET_RECRUITINGTorino, 10154, Italy
-
Research Site
WITHDRAWNVerona, 37126, Italy
-
Research Site
NOT_YET_RECRUITINGLodz, 92-213, Poland
-
Research Site
NOT_YET_RECRUITINGBarcelona, 08025, Spain
-
Research Site
NOT_YET_RECRUITINGMadrid, 28041, Spain
-
Research Site
NOT_YET_RECRUITINGManchester, M13 9WL, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
surovatamig
What this could lead to
If successful, this could point toward a new treatment option for people with primary membranous nephropathy, potentially reducing protein in the urine and improving kidney function.
What could go wrong
This is an early Phase 2 trial with only 43 participants, so results may not apply to everyone. The drug may cause side effects or fail to show clear benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.